4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
10 nov. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
- Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3,...
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
03 nov. 2022 09h45 HE
|
4D Molecular Therapeutics, Inc.
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients Cohort 1 safety and tolerability...
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
26 oct. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
27 sept. 2022 16h10 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
20 sept. 2022 16h15 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...